

For clinical trial “Multicenter, double-blind, randomized clinical trial to evaluate the efficacy of calcifediol soft capsules versus placebo in reducing hospital admissions in patients with a positive diagnostic test for COVID-19.”

Protocol: HIDR-0721/COV, version 1.1, dated 2021 June 1st
EudraCT number: 2021-000316-31
Sponsor: FAES FARMA S.A.

It was approved by the Ethics Committee *CEIm Fundacio Investigacio en Atencio Primaria Jordi Gol i Gurina - IDIAP Jordi Gol* on date July 5th, 2021 and authorized by the *Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)* on date July 15th, 2021.

However, it was decided to prematurely finalize the study on August 30th, 2021, given that the advance of vaccination against COVID-19 and the decrease in the incidence of the disease made it possible to foresee that the recruitment and the objectives set in the clinical trial would not be achieved.

The AEMPS and the Ethics Committee were informed of the premature finalization of the study on September 14th, 2021.

Since the study was not started in the participating centers and patients were not included in the study, the **lack of results for this clinical trial is reported.**



Dr. Nieves Fernández Hernando
Head of Clinical Research
R&D and Innovation Department
FAES FARMA, S.A